TCF4 and breast cancer: Chiang et al. found β-catenin/TCF4 binding sites in the promoter of miR-182 cluster and showed that the genetic or pharmacological inhibition of β-catenin impacted negatively on miR-182 levels in breast cancer cell lines [22].